Equities research analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to announce $9.65 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Strongbridge Biopharma’s earnings, with estimates ranging from $9.06 million to $10.40 million. Strongbridge Biopharma reported sales of $8.07 million in the same quarter last year, which would suggest a positive year over year growth rate of 19.6%. The firm is scheduled to announce its next quarterly earnings results on Thursday, November 4th.
According to Zacks, analysts expect that Strongbridge Biopharma will report full-year sales of $38.21 million for the current financial year, with estimates ranging from $36.72 million to $39.70 million. For the next fiscal year, analysts forecast that the business will post sales of $60.61 million, with estimates ranging from $58.10 million to $64.36 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Strongbridge Biopharma.
Strongbridge Biopharma (NASDAQ:SBBP) last announced its quarterly earnings data on Thursday, August 5th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.09). Strongbridge Biopharma had a negative return on equity of 66.82% and a negative net margin of 115.67%. The business had revenue of $10.04 million during the quarter, compared to analyst estimates of $8.83 million.
Shares of SBBP traded down $0.13 during midday trading on Monday, hitting $1.99. The stock had a trading volume of 179,928 shares, compared to its average volume of 905,837. Strongbridge Biopharma has a fifty-two week low of $1.85 and a fifty-two week high of $4.26. The business has a 50-day simple moving average of $2.27 and a two-hundred day simple moving average of $2.57. The firm has a market cap of $134.98 million, a P/E ratio of -2.65 and a beta of 1.58. The company has a current ratio of 3.00, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38.
Hedge funds have recently bought and sold shares of the stock. Worth Venture Partners LLC boosted its holdings in shares of Strongbridge Biopharma by 22.5% during the first quarter. Worth Venture Partners LLC now owns 550,196 shares of the biotechnology company’s stock worth $1,519,000 after purchasing an additional 101,150 shares during the period. Acadian Asset Management LLC acquired a new stake in Strongbridge Biopharma in the first quarter valued at approximately $177,000. Dimensional Fund Advisors LP lifted its stake in Strongbridge Biopharma by 55.1% in the first quarter. Dimensional Fund Advisors LP now owns 214,041 shares of the biotechnology company’s stock valued at $590,000 after acquiring an additional 76,054 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in Strongbridge Biopharma in the first quarter valued at approximately $108,000. Finally, BlackRock Inc. lifted its stake in Strongbridge Biopharma by 4.0% in the first quarter. BlackRock Inc. now owns 2,197,121 shares of the biotechnology company’s stock valued at $6,064,000 after acquiring an additional 85,496 shares during the last quarter. Institutional investors and hedge funds own 52.03% of the company’s stock.
About Strongbridge Biopharma
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.
Read More: Inflation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.